JTP 3399

Drug Profile

JTP 3399

Latest Information Update: 04 Sep 1997

Price : $50

At a glance

  • Originator Japan Tobacco
  • Developer Japan Tobacco; Mitsubishi Pharma Corporation
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Prolyl endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Dementia

Most Recent Events

  • 04 Sep 1997 Discontinued-Preclinical for Dementia in Japan (Unknown route)
  • 21 Jan 1997 Preclinical development for Dementia in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top